Loading company…
Syremis Therapeutics develops treatments for mental health conditions.
Founded in 2025, Syremis Therapeutics is based in Petah Tikva, Israel, and also located in Boston, MA. In December 2025, it raised USD 165 million in Series A funding co-led by Dexcel Pharma Technologies Ltd. and Third Rock Ventures, with Bain Capital Life Sciences, GV, QVT Financial and Pictet Alternative Advisors participating. The funding will support ST-905 through clinical proof of concept and ST-901 into Phase 1 development for mental health conditions.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in